TANGO2 Deficiency Disorder: Disease-Characteristics Research Report

Scope and evidence note. This synthesis emphasizes primary human and experimental studies through 2024. The retrieved bibliographic records did not expose PMID fields reliably; therefore, DOI and ClinicalTrials.gov URLs are supplied rather than inferred. Frequency estimates come from selected rare-disease cohorts and should not be interpreted as population prevalence. Short quotations are reproduced only where supported by retrieved abstracts.

Executive summary

TANGO2 deficiency disorder (TDD) is a rare, autosomal-recessive, multisystem Mendelian disease caused by biallelic pathogenic loss-of-function variants in TANGO2 at 22q11.21. Its defining combination is neurodevelopmental impairment plus stress-triggered metabolic crises, rhabdomyolysis, QT prolongation, malignant ventricular arrhythmias, and sometimes transient cardiomyopathy. Neurologic deterioration, seizures, ataxia, movement abnormalities, hypothyroidism, feeding problems, and episodic “TANGO2 spells” broaden the phenotype. Illness, fever, fasting, dehydration, reduced food intake, physical exertion, heat, and possibly selected anesthetics can precipitate episodes. The leading immediate threat is arrhythmic cardiac arrest during a metabolic crisis. (heiman2022mitochondrialdysfunctionassociated pages 1-2, miyake2022cardiaccrisescardiac pages 1-2, berat2021clinicalandbiological pages 1-7)

The best-supported mechanistic model is no longer simply a generic primary respiratory-chain disorder. Evidence instead converges on stress-sensitive disruption of lipid/acyl-CoA homeostasis, phosphatidic-acid and glycerolipid metabolism, membrane trafficking, and context-dependent mitochondrial function, causing ROS/lipid peroxidation and energetic/membrane failure in skeletal muscle, cardiomyocytes, and neural tissues. Important uncertainties remain about TANGO2’s exact biochemical activity, subcellular localization, and proposed role in heme transport. (heiman2022mitochondrialdysfunctionassociated pages 1-2, kim2023intrinsicandextrinsic pages 1-3, lujan2023defectsinlipid pages 1-2)

A major 2023–2024 development is convergent evidence for B vitamins: pantothenate/B5 rescues Drosophila and human-cell defects; folate/B9 nearly abolishes arrhythmias in patient-derived cardiomyocytes; and retrospective natural-history observations associate multivitamin/B-complex use with fewer crises. These findings are biologically compelling but not yet validated in randomized clinical trials. (asadi2023vitaminb5a pages 6-8, xu2024folateasa pages 1-2, asadi2023vitaminb5a pages 8-9)

The following table summarizes the principal evidence base.

Table: This table summarizes the strongest available evidence across clinical, mechanistic, therapeutic, and implementation domains for TANGO2 deficiency disorder. It highlights where the evidence is strongest and where major limitations remain.

1. Disease information

Definition and identifiers

TDD is an autosomal-recessive metabolic encephalomyopathic and arrhythmia syndrome caused by biallelic pathogenic variants in TANGO2. Open Targets maps it to MONDO:0018820, “recurrent metabolic encephalomyopathic crises–rhabdomyolysis–cardiac arrhythmia–intellectual disability syndrome,” associated with TANGO2/ENSG00000183597. The phenotype is cited as OMIM/MIM 616878. (OpenTargets Search: TANGO2 deficiency disorder-TANGO2, heiman2022mitochondrialdysfunctionassociated pages 1-2)

Common names include:

• TANGO2 deficiency disorder/disease;
• TANGO2-related disorder;
• TANGO2-related metabolic encephalomyopathic crises;
• metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration;
• TANGO2-related metabolic encephalopathy and arrhythmias, sometimes abbreviated TRMEA;
• recurrent metabolic encephalomyopathic crises–rhabdomyolysis–cardiac arrhythmia–intellectual disability syndrome.

No disease-specific ICD-10, ICD-11, or MeSH identifier was established in the retrieved evidence; clinical coding generally requires phenotype-level codes for genetic/metabolic disease, rhabdomyolysis, arrhythmia, epilepsy, developmental disorder, or hypothyroidism. A dedicated SNOMED CT concept was likewise not verified.

Evidence granularity. The literature combines individual medical records and biospecimens with aggregated disease-level resources. Human cohorts are retrospective or observational and include 9-, 14-, 20-, 27-, and 73-patient series; experimental evidence comes from patient fibroblasts/myoblasts, HepG2 cells, patient-derived iPSC cardiomyocytes, Drosophila, zebrafish, and mice. (miyake2022cardiaccrisescardiac pages 1-2, berat2021clinicalandbiological pages 12-17, dines2019tango2expandingthe pages 5-6, mingirulli2020clinicalpresentationand pages 1-2, sandkuhler2026crossspeciesevaluationof pages 15-16)

2. Etiology, risk, protection, and gene–environment interaction

Causal factors

The necessary cause is biallelic germline pathogenic variation in TANGO2, usually resulting in absent or severely reduced protein/function. Environmental agents do not independently cause the Mendelian disorder. Rather, they reveal the latent metabolic vulnerability and determine crisis timing and severity. (heiman2022mitochondrialdysfunctionassociated pages 1-2, owlett2024multicenterappraisalof pages 1-3)

Genetic risk factors

Reported pathogenic classes include multiexon deletions, nonsense, frameshift, canonical splice, small in-frame deletion, and missense variants. Important examples are the recurrent exon 3–9 deletion, c.460G>A (p.Gly154Arg), c.262C>T (p.Arg88*), c.220A>C (p.Thr74Pro), c.380+1G>A, and c.711-3C>G, the last experimentally associated with aberrant splicing. In one early dataset, the exon 3–9 deletion was prominent among European-ancestry cases, whereas p.Gly154Arg was recurrent in Hispanic/Latino cases; these are ancestry-associated observations, not universal founder-frequency estimates. (berat2021clinicalandbiological pages 12-17, mingirulli2020clinicalpresentationand pages 2-3, dines2019tango2expandingthe pages 5-6, mingirulli2020clinicalpresentationand pages 1-2)

TANGO2 lies in the recurrently deleted 22q11.2/DiGeorge region. A person with a 22q11.2 deletion that removes one TANGO2 allele is at risk of TDD if the remaining allele carries a pathogenic variant. A 2024 multicenter study screened 435 people with 22q11.2 deletion syndrome: 21 met symptom-based testing criteria, 9 underwent sequencing/deletion-duplication analysis, and none was confirmed, illustrating both low absolute yield and the danger of symptom overlap. (owlett2024multicenterappraisalof pages 1-3)

Environmental and lifestyle risk factors

Established crisis triggers are intercurrent illness—especially febrile or viral illness—fasting, dehydration, reduced intake, heat, and physical exertion. Selected anesthetic exposures and possibly carnitine supplementation were proposed as additional triggers in a 20-patient cohort; these observations require cautious interpretation and specialist review rather than blanket contraindication. (kim2023intrinsicandextrinsic pages 1-3, NCT05374616 chunk 1, berat2021clinicalandbiological pages 1-7)

Smoking, alcohol, pollution, occupational exposure, radiation, and chronic dietary patterns have no demonstrated etiologic role. Infectious organisms are triggers, not causal pathogens, and TDD is not communicable.

Protective factors

Avoiding prolonged fasting and dehydration, prompt treatment of illness, early carbohydrate-containing fluids plus complete nutrition, and avoidance of unnecessary heat/exertional stress during illness are clinically plausible protective measures. Glucose-containing fluids alone did not reliably prevent cardiac crisis; adequate feeding and micronutrient provision appear important. (miyake2022cardiaccrisescardiac pages 8-9)

B-complex or multivitamin supplementation is the leading candidate environmental protective factor. Human support remains observational, while B5 and B9 have direct rescue evidence in model systems. No protective TANGO2 allele or validated modifier gene has been identified. Intrafamilial variability strongly suggests modifiers, but none is established. (heiman2022mitochondrialdysfunctionassociated pages 1-2, xu2024folateasa pages 1-2, asadi2023vitaminb5a pages 8-9)

Gene–environment causal interaction

A useful causal model is:

biallelic TANGO2 loss → impaired lipid/acyl-CoA and membrane homeostasis ± mitochondrial/ER–Golgi dysfunction → reduced reserve in muscle, heart, and nervous system → fasting/illness/heat/exertion increases substrate demand and oxidative stress → rhabdomyolysis and metabolic decompensation → QT prolongation/cardiomyopathy → polymorphic VT, cardiac arrest, or death. (kim2023intrinsicandextrinsic pages 1-3, lujan2023defectsinlipid pages 1-2)

3. Phenotypes

Core phenotype frequencies and characteristics

In a 20-patient cohort, neurodevelopmental delay occurred in 17/20 (85%), acute metabolic crises in 17/20 (85%), and hypothyroidism in 12/20 (60%). Among the 17 with crises, rhabdomyolysis occurred in 15/17 (88%), neurologic manifestations in 14/17 (82%), and cardiac findings in 12/17 (71%). Long QT occurred in 10/17, Brugada-like pattern in 2/17, and arrhythmia in 6/17. (berat2021clinicalandbiological pages 1-7)

Suggested phenotype annotations follow; frequencies are cohort-specific.

• Global developmental delay/intellectual disability—usually infancy or childhood onset, variable severity, often progressive or worsened after crises; poor speech is common. Suggested HPO: Global developmental delay (HP:0001263), Intellectual disability (HP:0001249), Delayed speech and language development (HP:0000750). Progressive delay preceded crises in 14/20 in one series. (berat2021clinicalandbiological pages 12-17, mingirulli2020clinicalpresentationand pages 2-3)
• Developmental regression/neurodegeneration—episodic or progressive, sometimes crisis-associated; major effects on communication, schooling, independence, and caregiving burden. HPO: Developmental regression (HP:0002376), Neurodevelopmental regression.
• Seizures/epilepsy—childhood onset, variable and occasionally treatment-resistant; generalized and myoclonic forms are reported. HPO: Seizure (HP:0001250), Generalized myoclonic seizure (HP:0002123). (dołega2024clinicalspectrumdiagnosis pages 4-7)
• Ataxia, gait abnormality, dysarthria, spasticity, dystonia, hypotonia—chronic progressive or episodic, causing falls and loss of mobility. HPO: Ataxia (HP:0001251), Gait disturbance (HP:0001288), Dysarthria (HP:0001260), Spasticity (HP:0001257), Dystonia (HP:0001332), Muscular hypotonia (HP:0001252). (dołega2024clinicalspectrumdiagnosis pages 4-7, mingirulli2020clinicalpresentationand pages 2-3)
• TANGO2 spells—transient ataxia, weakness, and dyskinesia, often after waking; physical activity, heat, or reduced intake may trigger episodes lasting minutes to hours. Suggested HPO: Episodic ataxia (HP:0002131), Episodic weakness, Dyskinesia. (dołega2024clinicalspectrumdiagnosis pages 4-7)
• Rhabdomyolysis/myalgia/weakness—episodic and potentially severe, generally precipitated by metabolic stress. HPO: Rhabdomyolysis (HP:0003201), Myalgia (HP:0003326), Muscle weakness (HP:0001324), Myoglobinuria (HP:0002913). Crisis CK has ranged from 419 to 400,000 U/L in reported cohorts; one French case reached 43,670 IU/L. (kim2023intrinsicandextrinsic pages 1-3, berat2021clinicalandbiological pages 12-17, mingirulli2020clinicalpresentationand pages 2-3)
• Metabolic crisis/encephalopathy—acute and episodic, with hypoglycemia, lactic/metabolic acidosis, hyperammonemia, elevated transaminases, and sometimes coma. HPO: Hypoglycemia (HP:0001943), Lactic acidosis (HP:0003128), Hyperammonemia (HP:0001987), Encephalopathy (HP:0001298), Elevated serum creatine kinase (HP:0003236). Baseline metabolic studies may be normal between episodes. (heiman2022mitochondrialdysfunctionassociated pages 1-2, berat2021clinicalandbiological pages 12-17)
• QT prolongation and ventricular arrhythmia—episodic, crisis-linked, rapidly life-threatening. HPO: Prolonged QT interval (HP:0001657), Ventricular tachycardia (HP:0004756), Torsade de pointes (HP:0001664), Cardiac arrest (HP:0001695). In 43 severe admissions involving 27 patients, QTc prolongation was universal, median QTc 547 ms, VT occurred in 78%, and cardiac arrest in 74%. (miyake2022cardiaccrisescardiac pages 1-2)
• Cardiomyopathy/ventricular dysfunction—usually crisis-associated and potentially reversible, but severe cases require ECMO or rarely transplantation. HPO: Cardiomyopathy (HP:0001638), Decreased left ventricular ejection fraction (HP:0012664). It occurred in 70% of severe cardiac-crisis admissions. (miyake2022cardiaccrisescardiac pages 1-2)
• Hypothyroidism/TSH elevation—chronic, variable, treatable. HPO: Hypothyroidism (HP:0000821), Elevated thyroid-stimulating hormone (HP:0002925). TSH elevation occurred in 8/9 patients in one series and hypothyroidism in 12/20 in another. (mingirulli2020clinicalpresentationand pages 2-3, berat2021clinicalandbiological pages 1-7)
• Feeding difficulty—chronic and functionally important; 8/14 had gastrointestinal/feeding involvement in one cohort, sometimes requiring gastrostomy. HPO: Feeding difficulties (HP:0011968), Gastrostomy tube feeding. (dines2019tango2expandingthe pages 5-6)
• Neuroimaging abnormalities—variable ventriculomegaly, cerebral/white-matter atrophy, white-matter change, or microcephaly. MRI was abnormal in 9/16 in one cohort. HPO: Cerebral atrophy (HP:0002059), Ventriculomegaly (HP:0002119), Abnormal cerebral white matter morphology (HP:0002500), Progressive microcephaly (HP:0000253). (berat2021clinicalandbiological pages 12-17)
• Hearing impairment is reported but insufficiently quantified. HPO: Hearing impairment (HP:0000365). (dołega2024clinicalspectrumdiagnosis pages 4-7)

No validated TDD-specific EQ-5D, SF-36, PROMIS, or quality-of-life dataset was identified. Nevertheless, recurrent ICU admission, neurodevelopmental disability, epilepsy, feeding support, mobility loss, and sudden-death risk imply major patient and caregiver burden.

4. Genetic and molecular information

Causal gene: TANGO2, approved name transport and Golgi organization 2 homolog; Ensembl ENSG00000183597; chromosome 22q11.21. The retrieved sources did not provide a verified HGNC numerical identifier, so none is inferred. (OpenTargets Search: TANGO2 deficiency disorder-TANGO2, heiman2022mitochondrialdysfunctionassociated pages 1-2)

Pathogenic variants are constitutional/germline and usually act through loss of function. Somatic causation, gain of function, dominant-negative effects, repeat expansions, mitochondrial-DNA variants, and epigenetic silencing are not established. Pathogenic/likely pathogenic classification should be assigned per ACMG/AMP using population rarity, segregation, predicted loss of function, RNA/protein findings, and phenotype concordance; individual ClinVar classifications must be checked against the current record at testing time.

Large deletions can involve exons 3–9 or arise as part of a broader 22q11.2 deletion. This makes copy-number analysis essential. The allele frequency estimates cited in an early clinical report—approximately 0.0013 for the 34-kb exon 3–9 deletion and 0.0026 for p.Gly154Arg—were ancestry-specific database observations and should not be treated as global carrier frequencies. (mingirulli2020clinicalpresentationand pages 2-3)

No validated modifier gene, protective allele, anticipation, or recurrent germline mosaicism mechanism is known. No disease-specific methylation signature or other epigenetic biomarker was identified. Variable expressivity within families is well documented. (heiman2022mitochondrialdysfunctionassociated pages 1-2, dines2019tango2expandingthe pages 5-6)

5. Environmental information

No toxin, radiation, pollution, occupational exposure, smoking, alcohol, or pathogen causes TDD. Fever/infection, fasting, dehydration, heat, exertion, and reduced intake are clinically important precipitants. Infectious-agent identity is generally less important than the associated catabolic state. Certain anesthetics were proposed as triggers; perioperative planning should therefore involve metabolic, anesthesia, and cardiology specialists. (kim2023intrinsicandextrinsic pages 1-3, berat2021clinicalandbiological pages 1-7)

Ordinary exercise has no demonstrated long-term preventive benefit and vigorous exertion during illness or fasting may be hazardous. Nutritional regularity and avoidance of catabolism are more relevant than a disease-specific macronutrient diet. No evidence supports tobacco/alcohol counseling as disease-specific therapy beyond general health recommendations.

6. Mechanism and pathophysiology

Current mechanistic model

Upstream: TANGO2 loss disturbs acyl-CoA/lipid handling and endomembrane organization. In TANGO2-deficient HepG2 cells and patient fibroblasts, lipidomics showed increased lysophosphatidic acid, decreased phosphatidic acid, reduced cardiolipin, and enlarged lipid droplets. The proposed biochemical lesion is insufficient acyl-CoA availability for LPA acylation to PA. (lujan2023defectsinlipid pages 1-2)

Intermediate: altered phospholipid and neutral-lipid composition impairs membrane integrity, lipid-droplet catabolism, mitochondrial membranes, ER/SR–Golgi trafficking, and fatty-acid utilization. Patient cells show delayed ER-to-Golgi transport, altered ER morphology, decreased stress oxygen consumption/ATP, impaired oleate or palmitate oxidation in some systems, and increased superoxide/ROS. Proteomics implicates fatty-acid oxidation, amino-acid metabolism, plasma membrane, ER–Golgi, and secretory pathways. (heiman2022mitochondrialdysfunctionassociated pages 1-2, kim2023intrinsicandextrinsic pages 1-3)

Downstream: nutrient deprivation or illness intensifies substrate shortage and oxidative stress, causing lipid peroxidation and energetic/membrane failure. Skeletal myofibers undergo necrosis/rhabdomyolysis; cardiomyocytes develop repolarization instability, QT prolongation, ventricular dysfunction, and VT; neural cells likely undergo episodic dysfunction and cumulative injury, producing encephalopathy, seizures, ataxia, and regression. (kim2023intrinsicandextrinsic pages 3-5, lujan2023defectsinlipid pages 1-2)

This framework reconciles conflicting energetic studies: one 20-patient investigation found no evidence of a constitutive primary energetic defect and largely normal baseline acylcarnitines/FGF21, whereas fibroblast and muscle models detect abnormalities under metabolic stress. Thus TDD is best viewed as a stress-sensitive lipid/membrane homeostasis disorder with secondary, context-dependent mitochondrial dysfunction, not a proven primary respiratory-chain enzyme deficiency. (berat2021clinicalandbiological pages 12-17, berat2021clinicalandbiological pages 1-7, heiman2022mitochondrialdysfunctionassociated pages 1-2)

Localization and protein function

TANGO2 has been detected predominantly at mitochondria and at mitochondria–ER–lipid-droplet contact regions in some mammalian systems; other work supports endomembrane, cytosolic, SR, Golgi, or mixed localization. Antibody and fusion-protein limitations contribute to disagreement. A direct acyl-CoA-binding function is plausible but was not definitively established by the 2023 studies retrieved here. Heme trafficking by homologues is an active comparative hypothesis, not yet a settled explanation for human TDD. (heiman2022mitochondrialdysfunctionassociated pages 1-2, kim2023intrinsicandextrinsic pages 3-5, lujan2023defectsinlipid pages 1-2, sandkuhler2026crossspeciesevaluationof pages 15-16)

Suggested ontology annotations

• GO biological process: intracellular lipid transport; phospholipid biosynthetic process; glycerolipid metabolic process; fatty-acid beta-oxidation; ER-to-Golgi vesicle-mediated transport; mitochondrial ATP synthesis; response to oxidative stress; regulation of membrane organization; skeletal-muscle tissue development.
• GO cellular component: mitochondrion; mitochondrial membrane; endoplasmic reticulum; Golgi apparatus; lipid droplet; sarcoplasmic reticulum; mitochondrion-associated ER membrane.
• Cell Ontology: skeletal muscle fiber/myocyte (CL:0000187); cardiomyocyte (CL:0000746); fibroblast (CL:0000057); neuron (CL:0000540); hepatocyte (CL:0000182).

Molecular profiling and advanced technologies

• Proteomics: broad changes in mitochondrial fatty-acid oxidation, ER–Golgi, plasma-membrane, amino-acid-metabolism, and secretory proteins. (mingirulli2020clinicalpresentationand pages 1-2, heiman2022mitochondrialdysfunctionassociated pages 1-2)
• Lipidomics: increased LPA, decreased PA/cardiolipin, enlarged lipid droplets, glycerolipid abnormalities, and enhanced stress sensitivity. (kim2023intrinsicandextrinsic pages 1-3, lujan2023defectsinlipid pages 1-2)
• Metabolomics: no validated diagnostic plasma signature; acylcarnitines and lactate may be normal between crises. (berat2021clinicalandbiological pages 12-17)
• iPSC electrophysiology/CRISPR: patient-derived cardiomyocytes recapitulated arrhythmia; wild-type TANGO2 expression or CRISPR correction rescued electrophysiology, supporting causality. (xu2024folateasa pages 1-2)
• No replicated single-cell, spatial-transcriptomic, or integrated human multi-omics atlas was identified through 2024.

Relevant abstract quotation from Lujan et al. (published March 2023): “Quantitative lipidomics revealed a marked increase in lysophosphatidic acid (LPA) and a concomitant decrease in its biosynthetic precursor phosphatidic acid (PA).” (lujan2023defectsinlipid pages 1-2)

7. Anatomical structures affected

Primary systems are:

• Nervous system: brain/cerebral white matter, cerebellar and motor networks; developmental, epileptic, ataxic, and movement phenotypes. Suggested UBERON: brain (UBERON:0000955), cerebral white matter (UBERON:0002437), cerebellum (UBERON:0002037).
• Skeletal muscle: recurrent myofiber injury and rhabdomyolysis. UBERON: skeletal muscle tissue (UBERON:0001134); CL: skeletal muscle fiber (CL:0000187).
• Heart: ventricular myocardium and cardiac conduction/repolarization system. UBERON: heart (UBERON:0000948), myocardium (UBERON:0002349); CL: cardiomyocyte (CL:0000746).
• Thyroid: frequent hypothyroidism/TSH elevation. UBERON: thyroid gland (UBERON:0002046).
• Kidney: secondary risk from myoglobinuria and severe rhabdomyolysis rather than proven primary renal disease. UBERON: kidney (UBERON:0002113).
• Liver/metabolic compartment: transaminase elevation and biochemical decompensation occur during crises; direct chronic hepatopathy is not established.

Subcellular structures include mitochondria, ER/SR, Golgi, lipid droplets, and organelle contact sites. No characteristic lateralization is reported; disease is systemic/bilateral.

8. Temporal development

Onset is usually infancy or childhood, reported from 4 months to 8 years. Neurodevelopmental or muscle abnormalities often precede the first metabolic/cardiac crisis. (dołega2024clinicalspectrumdiagnosis pages 1-4, mingirulli2020clinicalpresentationand pages 2-3)

The course is lifelong and combines:

1. a chronic neurodevelopmental phenotype;
2. intermittent spells and metabolic crises;
3. cumulative or stepwise neurologic regression in some patients;
4. potentially reversible crisis-associated cardiac dysfunction;
5. persistent risk of sudden death.

There is no formal stage system. A practical clinical staging model is baseline/stable, prodromal catabolic illness, metabolic/rhabdomyolysis crisis, and cardiac crisis/recovery. Critical intervention windows are the earliest phase of illness or fasting, the onset of CK/QTc elevation, and the period before ventricular ectopy progresses to VT. Spontaneous genetic remission does not occur; crisis manifestations can resolve, but developmental disability generally persists.

9. Inheritance and population

Inheritance is autosomal recessive. Parents are usually heterozygous carriers; each pregnancy has a 25% affected, 50% carrier, and 25% unaffected/non-carrier probability when both parental variants are known. Penetrance for biallelic severe loss-of-function appears high, but age-dependent penetrance for individual manifestations and marked variable expressivity complicate counseling.

Consanguinity can increase risk for homozygous alleles but is not required. Founder/population enrichment has been reported for the exon 3–9 deletion in European-ancestry cases, p.Gly154Arg in Hispanic/Latino cases, and exon 4–6 deletion in some Arab families. These patterns require confirmation in population-scale datasets. (heiman2022mitochondrialdysfunctionassociated pages 1-2, mingirulli2020clinicalpresentationand pages 2-3)

A 2024 paper cited a carrier rate near 1 in 350; the same review literature estimated prevalence near 1 per million and approximately 8,000 affected persons worldwide. These figures are uncertain extrapolations, not registry-derived incidence estimates. No reliable annual incidence, sex ratio, or geographic prevalence map exists. Both sexes are affected; no sex-linked mechanism is expected. (owlett2024multicenterappraisalof pages 1-3, dołega2024clinicalspectrumdiagnosis pages 1-4)

There is no repeat-mediated anticipation. Germline mosaicism is theoretically possible for any de novo event but is not a recognized major feature. Cascade testing is appropriate for siblings and extended relatives when familial variants are known.

10. Diagnostics

When to suspect TDD

Suspect TDD in a child with developmental delay, regression, episodic ataxia or weakness, seizures, unexplained CK elevation/rhabdomyolysis, hypoglycemia/lactic acidosis during illness, hypothyroidism, QT prolongation, Brugada-like pattern, or ventricular arrhythmia—especially when several coexist. Consider it specifically in symptomatic individuals with 22q11.2 deletion syndrome. (owlett2024multicenterappraisalof pages 1-3, miyake2022cardiaccrisescardiac pages 1-2)

Acute clinical testing

During illness/crisis, obtain serial:

• CK, electrolytes including magnesium and calcium, glucose, blood gas/bicarbonate, lactate, ammonia, AST/ALT, renal function, urinalysis/myoglobin;
• continuous ECG/telemetry with repeated QTc assessment;
• echocardiography and ventricular-function monitoring;
• EEG for encephalopathy or seizure;
• brain MRI for regression, focal findings, or unexplained neurologic progression.

Normal baseline acylcarnitines, amino acids, lactate, carnitine, or respiratory-chain studies do not exclude TDD. No validated enzyme assay or circulating biomarker exists. Western blot or research fibroblast functional testing can support loss of protein/function but is not the standard definitive test. (berat2021clinicalandbiological pages 12-17, dołega2024clinicalspectrumdiagnosis pages 4-7)

Genetic testing strategy

1. Use a neurodevelopmental/epilepsy, rhabdomyolysis/metabolic, cardiomyopathy/arrhythmia, or comprehensive Mendelian panel that explicitly includes TANGO2.
2. Require both sequence analysis and exon-level deletion/duplication analysis because multiexon deletions are common.
3. If panel testing is negative or phenotype is atypical, use trio WES or WGS with copy-number and structural-variant calling.
4. In a person with 22q11.2 deletion and suggestive features, sequence and assess copy number of the remaining TANGO2 allele.
5. Confirm phase/segregation in parents and apply ACMG/AMP criteria. RNA analysis may clarify splice variants.

Chromosomal microarray can detect a 22q11.2 deletion or sufficiently large TANGO2 deletion but may miss small exon-level or sequence variants. Karyotype and FISH are not adequate stand-alone tests; mtDNA and repeat-expansion testing are not indicated unless the differential independently warrants them.

Differential diagnosis

Consider fatty-acid oxidation disorders, mitochondrial cytopathies, glycogen-storage/metabolic myopathies, RYR1- and LPIN1-related rhabdomyolysis, PNKD, channelopathies/long-QT syndromes, Brugada syndrome, CPVT, epilepsy syndromes, and primary 22q11.2 deletion syndrome. TDD is distinguished by the combined neurodevelopmental–rhabdomyolysis–metabolic–arrhythmic phenotype and biallelic TANGO2 variants.

There are no universally validated clinical diagnostic criteria independent of molecular confirmation. No routine newborn biochemical screen exists. DNA-first newborn screening has been discussed because TDD lacks a reliable dried-blood-spot biochemical footprint, but evidence and implementation criteria remain insufficient. (dołega2024clinicalspectrumdiagnosis pages 1-4)

11. Outcome and prognosis

Population-level survival curves, 5-/10-year survival, and life expectancy are unavailable. Prognosis is highly variable and influenced by crisis frequency, early recognition, nutritional status, and access to intensive cardiac support.

Historical small cohorts demonstrate substantial mortality. In a 14-patient series, 5/14 died, four primarily from arrhythmia. In the severe cardiac-crisis cohort, 10/27 (37%) died, six from arrhythmia; these are referral-enriched estimates and overstate risk for all diagnosed patients. (miyake2022cardiaccrisescardiac pages 1-2, dines2019tango2expandingthe pages 5-6)

During severe cardiac crises, cardiomyopathy occurred in 70%, cardiac arrest in 74%, and VT in 78%. ECMO-supported survival from arrhythmia was reported in 5/6 supported patients, suggesting that aggressive escalation can be lifesaving. (miyake2022cardiaccrisescardiac pages 1-2)

Long-term morbidity includes intellectual and speech impairment, epilepsy, ataxia/spasticity/dystonia, mobility limitations, feeding dependence, recurrent hospitalization, and anxiety related to unpredictable crises. Acute kidney injury can follow severe rhabdomyolysis. Prognostic biomarkers beyond clinical trajectory, CK, QTc, ventricular function, and crisis burden are not validated.

12. Treatment and real-world implementation

There is no approved curative or genotype-replacing therapy. Care should be coordinated by metabolic genetics, cardiology/electrophysiology, neurology, endocrinology, nutrition, rehabilitation, and intensive care.

Baseline and preventive management

• Regular meals and avoidance of prolonged fasting/dehydration.
• Written emergency/sick-day plan and early hospital evaluation for fever, reduced intake, weakness, dark urine, seizure, or palpitations.
• B-complex or multivitamin supplementation containing B5 and folate is increasingly used in practice, but dose, formulation, and efficacy are not trial-standardized.
• Periodic ECG, thyroid testing, neurologic/developmental assessment, and individualized CK/cardiac surveillance.

Suggested MAXO concepts: genetic counseling; dietary management; vitamin supplementation; electrocardiographic monitoring; echocardiography; thyroid-function monitoring.

Acute metabolic/cardiac crisis

Provide prompt dextrose-containing fluids while restoring full enteral or parenteral nutrition, correct electrolytes, monitor CK/renal status, avoid QT-prolonging agents, and use continuous telemetry with frequent echocardiography. Glucose alone may be insufficient. Early nutrition, including micronutrients, is emphasized. (miyake2022cardiaccrisescardiac pages 8-9)

For malignant arrhythmia, reported strategies include IV magnesium, isoproterenol, overdrive atrial pacing, intensive electrolyte correction, and ECMO for refractory instability. Amiodarone and lidocaine were reported as potentially ineffective or aggravating in this specific crisis physiology; drug selection should be directed by a specialist TDD electrophysiology team rather than generic long-QT algorithms. (dołega2024clinicalspectrumdiagnosis pages 4-7, miyake2022cardiaccrisescardiac pages 8-9)

Suggested MAXO concepts: intravenous fluid therapy; glucose administration; electrolyte replacement; continuous cardiac monitoring; temporary cardiac pacing; extracorporeal membrane oxygenation; mechanical ventilation; renal-function monitoring.

Symptom-directed treatment

• Epilepsy: levetiracetam or valproate have been used; selection should account for metabolic and cardiac safety.
• Spasticity/dystonia: baclofen, clonazepam, botulinum toxin, plus physical/occupational therapy.
• Hypothyroidism: levothyroxine.
• Feeding/speech/mobility: nutrition support, gastrostomy when necessary, speech therapy, PT/OT, orthotics and assistive devices.
• Heart failure during crisis: conventional ICU inotropes and heart-failure medications are individualized; rare severe cardiomyopathy has required transplantation. (dołega2024clinicalspectrumdiagnosis pages 4-7)

B-vitamin evidence

Vitamin B5/pantothenate—preclinical: In Drosophila, 2–4 mM B5 approximately doubled median starvation survival (~25 versus 12 hours), reduced heat-induced seizures by about 95%, prolonged seizure latency, and improved locomotor/behavioral measures. It restored ER-to-Golgi transport toward control rates in human TANGO2-deficient fibroblasts. The study’s abstract states: “vitamin B5 specifically improves multiple defects associated with TANGO2 loss-of-function in Drosophila and rescues membrane trafficking defects in human cells.” (asadi2023vitaminb5a pages 6-8, asadi2023vitaminb5a pages 1-3)

Folate/B9—iPSC cardiomyocytes: High-dose folate “virtually abolishes arrhythmias” in patient-derived iPSC cardiomyocytes; methotrexate blocked the benefit, supporting a requirement for intracellular folate metabolism. Wild-type TANGO2 expression and CRISPR correction also rescued the electrophysiologic phenotype. Human clinical support is observational, not randomized. (xu2024folateasa pages 1-2)

The apparently different B5-versus-B9 findings likely reflect assay and tissue specificity: B5 was strongest for fly systemic/trafficking phenotypes, whereas B9 was strongest in cardiomyocyte electrophysiology. A B-complex strategy may therefore be more rational than assuming a single active vitamin, but efficacy, dose, and toxicity require prospective study.

Experimental therapies and trials

No interventional gene, cell, RNA, CRISPR, or controlled drug trial was identified. NCT05374616 is a recruiting observational natural-history and biorepository study at Baylor, planned enrollment 300, started May 2018, estimated completion January 2030; it tracks metabolic/cardiac crises and collects blood, saliva, and fibroblasts. URL: https://clinicaltrials.gov/study/NCT05374616. (NCT05374616 chunk 1)

No TDD-specific pharmacogenomic rule is established.

13. Prevention

Primary prevention of inherited disease: impossible after conception through lifestyle modification. Options for at-risk families include carrier testing, partner testing, preimplantation genetic testing, prenatal diagnosis, donor gametes, and informed reproductive planning.

Secondary prevention: cascade testing of siblings/relatives and molecular diagnosis before a first crisis; targeted testing in symptomatic people with 22q11.2 deletion; possible future DNA-first newborn screening. Population newborn screening is not currently established. (owlett2024multicenterappraisalof pages 1-3, dołega2024clinicalspectrumdiagnosis pages 1-4)

Tertiary prevention: avoid fasting/dehydration, institute sick-day plans, provide early nutrition and B-complex supplementation under clinical supervision, monitor QTc and thyroid function, treat seizures/movement disorders, and prepare rapid escalation pathways for pacing/ECMO. Vaccination according to routine schedules may indirectly reduce febrile illnesses but is not TDD-specific immunotherapy.

Genetic counseling should explain autosomal-recessive recurrence, variable expressivity, limitations of prognosis, and the need to test deletion/duplication as well as sequence variants.

14. Other species and natural disease

No naturally occurring veterinary TANGO2-deficiency syndrome or breed predisposition was established in the retrieved evidence. There is no transmission or zoonotic potential.

Orthologues/homologues have been studied in:

• Drosophila melanogaster—NCBI Taxon 7227;
• Danio rerio—Taxon 7955;
• Mus musculus—Taxon 10090;
• Caenorhabditis elegans—Taxon 6239;
• yeast and bacterial homologues in comparative biochemical work.

Evolutionary conservation supports roles in lipid/endomembrane biology and possibly heme handling, but the homologues are not functionally identical. Orthologue-specific NCBI Gene and VBO identifiers were not verified in the retrieved records and should be sourced directly before database ingestion.

15. Model organisms and experimental systems

Drosophila

Loss-of-function flies reproduce starvation sensitivity, heat-induced seizure susceptibility, impaired climbing/locomotion, learning deficits, and altered behavior. B5 robustly rescues several phenotypes; B3 provides weaker rescue. Advantages are rapid whole-organism stress and supplementation assays; limitations include a non-mammalian heart and incomplete correspondence to human neurodevelopment. (asadi2023vitaminb5a pages 6-8, asadi2023vitaminb5a pages 1-3)

Zebrafish

Mutants show growth impairment, smaller myofibers, abnormal glycerolipid pathways, stress-induced skeletal-muscle injury, early lethality, and approximately 96% mortality by three months in one model. Tango2 localizes near SR, Golgi, and mitochondria. This model is well suited to rhabdomyolysis, lipidomics, environmental triggers, and high-throughput rescue studies, but does not reproduce every human cardiac/neurodevelopmental feature. (kim2023intrinsicandextrinsic pages 1-3, kim2023intrinsicandextrinsic pages 3-5)

Mouse

Reported knockout mice have relatively normal development, lifespan, and gross physiology, making them a poor constitutive phenocopy under standard conditions. Stress paradigms, tissue-specific knockouts, or sensitized backgrounds may be needed. (kim2023intrinsicandextrinsic pages 3-5, casey2022glycerolipiddefectsin pages 1-5)

Human cellular models

Patient fibroblasts and myoblasts permit trafficking, lipidomic, respiration, ROS, and nutrient-stress studies but may not model excitable tissues. Patient-derived iPSC cardiomyocytes reproduce electrophysiologic abnormalities and respond to wild-type gene replacement, CRISPR correction, and folate, making them the most disease-proximal current arrhythmia platform. (xu2024folateasa pages 1-2, heiman2022mitochondrialdysfunctionassociated pages 1-2)

No validated cerebral organoid, skeletal-muscle organoid, single-cell disease atlas, or spatial-transcriptomic model was identified through 2024.

Evidence-weighted conclusions

1. Established: TDD is a biallelic TANGO2 loss-of-function disorder with high-risk stress-triggered rhabdomyolysis and ventricular arrhythmia superimposed on a variable neurodevelopmental syndrome.
2. Strong clinical signal: QT prolongation is nearly universal during severe cardiac crises, and VT, cardiac arrest, cardiomyopathy, and mortality are common in crisis-enriched cohorts. (miyake2022cardiaccrisescardiac pages 1-2)
3. Best current mechanism: impaired lipid/acyl-CoA and membrane homeostasis with secondary stress-dependent mitochondrial and trafficking dysfunction; a simple primary respiratory-chain defect is inadequate. (berat2021clinicalandbiological pages 1-7, lujan2023defectsinlipid pages 1-2)
4. Most important recent therapeutic development: convergent B-vitamin rescue evidence—B5 for systemic/trafficking defects and B9 for cardiomyocyte arrhythmia—plus observational human protection. It is promising but not yet randomized-trial evidence. (asadi2023vitaminb5a pages 6-8, xu2024folateasa pages 1-2)
5. Knowledge gaps: true prevalence, penetrance by genotype, modifier genes, prospective treatment effects/doses, validated biomarkers, standardized acute protocols, and faithful mammalian models.

Key recent sources and URLs

• Xu et al., June 2024, JCI Insight, “Folate as a potential treatment…” https://doi.org/10.1172/jci.insight.171005. (xu2024folateasa pages 1-2)
• Owlett et al., June 2024, American Journal of Medical Genetics A, 22q11.2 screening appraisal: https://doi.org/10.1002/ajmg.a.63778. (owlett2024multicenterappraisalof pages 1-3)
• Dołęga et al., August 2024, clinical review: https://doi.org/10.12775/qs.2024.21.54001. (dołega2024clinicalspectrumdiagnosis pages 1-4)
• Asadi et al., 2023, vitamin B5 rescue: https://doi.org/10.1002/jimd.12579. (asadi2023vitaminb5a pages 6-8)
• Lujan et al., March 2023, lipid homeostasis: https://doi.org/10.7554/eLife.85345. (lujan2023defectsinlipid pages 1-2)
• Kim et al., September 2023, zebrafish/stress susceptibility: https://doi.org/10.1242/dmm.050092. (kim2023intrinsicandextrinsic pages 1-3)
• Miyake et al., October 2022, cardiac crises: https://doi.org/10.1016/j.hrthm.2022.05.009. (miyake2022cardiaccrisescardiac pages 1-2)
• Baylor natural-history study: https://clinicaltrials.gov/study/NCT05374616. (NCT05374616 chunk 1)

References

1. (heiman2022mitochondrialdysfunctionassociated pages 1-2): Paige Heiman, Al-Walid Mohsen, Anuradha Karunanidhi, Claudette St Croix, Simon Watkins, Erik Koppes, Richard Haas, Jerry Vockley, and Lina Ghaloul-Gonzalez. Mitochondrial dysfunction associated with tango2 deficiency. Scientific Reports, Feb 2022. URL: https://doi.org/10.1038/s41598-022-07076-9, doi:10.1038/s41598-022-07076-9. This article has 51 citations and is from a peer-reviewed journal.

2. (miyake2022cardiaccrisescardiac pages 1-2): Christina Y. Miyake, Erica J. Lay, Cheyenne M. Beach, Scott R. Ceresnak, Caridad M. Delauz, Taylor S. Howard, Christopher M. Janson, Kate Jardine, Prince J. Kannankeril, Maina Kava, Jeffrey J. Kim, Leonardo Liberman, Scott L. Macicek, Tam Dam Pham, Terry Robertson, Santiago O. Valdes, Gregory Webster, Sara B. Stephens, Diana M. Milewicz, Mahshid Azamian, Saad A. Ehsan, Kimberly M. Houck, Claudia Soler-Alfonso, Kevin E. Glinton, Mustafa Tosur, Na Li, Weiyi Xu, Seema R. Lalani, and Lilei Zhang. Cardiac crises: cardiac arrhythmias and cardiomyopathy during tango2 deficiency related metabolic crises. Heart Rhythm, 19:1673-1681, Oct 2022. URL: https://doi.org/10.1016/j.hrthm.2022.05.009, doi:10.1016/j.hrthm.2022.05.009. This article has 37 citations and is from a peer-reviewed journal.

3. (berat2021clinicalandbiological pages 1-7): Claire‐Marine Bérat, Sebastian Montealegre, Arnaud Wiedemann, Malou Le Corronc Nuzum, Amélie Blondel, Hugo Debruge, Aline Cano, Brigitte Chabrol, Célia Hoebeke, Michel Polak, Athanasia Stoupa, François Feillet, Stéphanie Torre, Nathalie Boddaert, Henri Bruel, Magalie Barth, Lena Damaj, Marie‐Thérèse Abi‐Wardé, Alexandra Afenjar, Jean‐François Benoist, Marine Madrange, Laure Caccavelli, Perrine Renard, Arnaud Hubas, Patrick Nusbaum, Clément Pontoizeau, Stéphanie Gobin, Peter van Endert, Chris Ottolenghi, Alice Maltret, and Pascale de Lonlay. Clinical and biological characterization of 20 patients with tango2 deficiency indicates novel triggers of metabolic crises and no primary energetic defect. Sep 2020. URL: https://doi.org/10.1002/jimd.12314, doi:10.1002/jimd.12314. This article has 43 citations and is from a peer-reviewed journal.

4. (kim2023intrinsicandextrinsic pages 1-3): Euri S. Kim, Jennifer G. Casey, Brian S. Tao, Arian Mansur, Nishanthi Mathiyalagan, E. Diane Wallace, Brandie M. Ehrmann, and Vandana A. Gupta. Intrinsic and extrinsic regulation of rhabdomyolysis susceptibility by tango2. Disease Models & Mechanisms, Sep 2023. URL: https://doi.org/10.1242/dmm.050092, doi:10.1242/dmm.050092. This article has 14 citations and is from a domain leading peer-reviewed journal.

5. (lujan2023defectsinlipid pages 1-2): Agustin Leonardo Lujan, Ombretta Foresti, Conor Sugden, Nathalie Brouwers, Alex Mateo Farre, Alessio Vignoli, Mahshid Azamian, Alicia Turner, Jose Wojnacki, and Vivek Malhotra. Defects in lipid homeostasis reflect the function of tango2 in phospholipid and neutral lipid metabolism. eLife, Mar 2023. URL: https://doi.org/10.7554/elife.85345, doi:10.7554/elife.85345. This article has 31 citations and is from a domain leading peer-reviewed journal.

6. (asadi2023vitaminb5a pages 6-8): Paria Asadi, Miroslav P. Milev, Djenann Saint‐Dic, Chiara Gamberi, and Michael Sacher. Vitamin b5, a coenzyme a precursor, rescues tango2 deficiency disease‐associated defects in drosophila and human cells. Journal of Inherited Metabolic Disease, 46:358-368, Dec 2023. URL: https://doi.org/10.1002/jimd.12579, doi:10.1002/jimd.12579. This article has 45 citations and is from a peer-reviewed journal.

7. (xu2024folateasa pages 1-2): Weiyi Xu, Yingqiong Cao, Sara B. Stephens, Maria Jose Arredondo, Yifan Chen, William Perez, Liang Sun, Andy C. Yu, Jean J. Kim, Seema R. Lalani, Na Li, Frank T. Horrigan, Francisco Altamirano, Xander H.T. Wehrens, Christina Y. Miyake, and Lilei Zhang. Folate as a potential treatment for lethal ventricular arrhythmias in tango2-deficiency disorder. JCI Insight, Jun 2024. URL: https://doi.org/10.1172/jci.insight.171005, doi:10.1172/jci.insight.171005. This article has 10 citations and is from a domain leading peer-reviewed journal.

8. (asadi2023vitaminb5a pages 8-9): Paria Asadi, Miroslav P. Milev, Djenann Saint‐Dic, Chiara Gamberi, and Michael Sacher. Vitamin b5, a coenzyme a precursor, rescues tango2 deficiency disease‐associated defects in drosophila and human cells. Journal of Inherited Metabolic Disease, 46:358-368, Dec 2023. URL: https://doi.org/10.1002/jimd.12579, doi:10.1002/jimd.12579. This article has 45 citations and is from a peer-reviewed journal.

9. (OpenTargets Search: TANGO2 deficiency disorder-TANGO2): Open Targets Query (TANGO2 deficiency disorder-TANGO2, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

10. (mingirulli2020clinicalpresentationand pages 2-3): Nadja Mingirulli, Angela Pyle, Denisa Hathazi, Charlotte L. Alston, Nicolai Kohlschmidt, Gina O'Grady, Leigh Waddell, Frances Evesson, Sandra B. T. Cooper, Christian Turner, Jennifer Duff, Ana Topf, Delia Yubero, Cristina Jou, Andrés Nascimento, Carlos Ortez, Angels García‐Cazorla, Claudia Gross, Maria O'Callaghan, Saikat Santra, Maryanne A. Preece, Michael Champion, Sergei Korenev, Efsthatia Chronopoulou, Majumdar Anirban, Germaine Pierre, Daniel McArthur, Kyle Thompson, Placido Navas, Antonia Ribes, Frederic Tort, Agatha Schlüter, Aurora Pujol, Raquel Montero, Georgia Sarquella, Hanns Lochmüller, Cecilia Jiménez‐Mallebrera, Robert W. Taylor, Rafael Artuch, Janbernd Kirschner, Sarah C. Grünert, Andreas Roos, and Rita Horvath. Clinical presentation and proteomic signature of patients with tango2 mutations. Journal of Inherited Metabolic Disease, 43:297-308, Aug 2019. URL: https://doi.org/10.1002/jimd.12156, doi:10.1002/jimd.12156. This article has 55 citations and is from a peer-reviewed journal.

11. (berat2021clinicalandbiological pages 12-17): Claire‐Marine Bérat, Sebastian Montealegre, Arnaud Wiedemann, Malou Le Corronc Nuzum, Amélie Blondel, Hugo Debruge, Aline Cano, Brigitte Chabrol, Célia Hoebeke, Michel Polak, Athanasia Stoupa, François Feillet, Stéphanie Torre, Nathalie Boddaert, Henri Bruel, Magalie Barth, Lena Damaj, Marie‐Thérèse Abi‐Wardé, Alexandra Afenjar, Jean‐François Benoist, Marine Madrange, Laure Caccavelli, Perrine Renard, Arnaud Hubas, Patrick Nusbaum, Clément Pontoizeau, Stéphanie Gobin, Peter van Endert, Chris Ottolenghi, Alice Maltret, and Pascale de Lonlay. Clinical and biological characterization of 20 patients with tango2 deficiency indicates novel triggers of metabolic crises and no primary energetic defect. Sep 2020. URL: https://doi.org/10.1002/jimd.12314, doi:10.1002/jimd.12314. This article has 43 citations and is from a peer-reviewed journal.

12. (owlett2024multicenterappraisalof pages 1-3): Laura D. Owlett, Bianca Zapanta, Sarah E. Sandkuhler, Elizabeth G. Ames, Scott E. Hickey, Samuel J. Mackenzie, and Joshua K. Meisner. Multicenter appraisal of comorbid tango2 deficiency disorder in patients with 22q11.2 deletion syndrome. American Journal of Medical Genetics Part A, Jun 2024. URL: https://doi.org/10.1002/ajmg.a.63778, doi:10.1002/ajmg.a.63778. This article has 4 citations.

13. (kim2023intrinsicandextrinsic pages 3-5): Euri S. Kim, Jennifer G. Casey, Brian S. Tao, Arian Mansur, Nishanthi Mathiyalagan, E. Diane Wallace, Brandie M. Ehrmann, and Vandana A. Gupta. Intrinsic and extrinsic regulation of rhabdomyolysis susceptibility by tango2. Disease Models & Mechanisms, Sep 2023. URL: https://doi.org/10.1242/dmm.050092, doi:10.1242/dmm.050092. This article has 14 citations and is from a domain leading peer-reviewed journal.

14. (asadi2023vitaminb5a pages 1-3): Paria Asadi, Miroslav P. Milev, Djenann Saint‐Dic, Chiara Gamberi, and Michael Sacher. Vitamin b5, a coenzyme a precursor, rescues tango2 deficiency disease‐associated defects in drosophila and human cells. Journal of Inherited Metabolic Disease, 46:358-368, Dec 2023. URL: https://doi.org/10.1002/jimd.12579, doi:10.1002/jimd.12579. This article has 45 citations and is from a peer-reviewed journal.

15. (NCT05374616 chunk 1): Seema Lalani. Natural History Study and Establishment of a Biorepository-TANGO2-related Disorder. Baylor College of Medicine. 2018. ClinicalTrials.gov Identifier: NCT05374616

16. (dines2019tango2expandingthe pages 5-6): Jennifer N. Dines, Katie Golden-Grant, Amy LaCroix, Alison M. Muir, Dianne Laboy Cintrón, Kirsty McWalter, Megan T. Cho, Angela Sun, J. Lawrence Merritt, Jenny Thies, Dmitriy Niyazov, Barbara Burton, Katherine Kim, Leah Fleming, Rachel Westman, Peter Karachunski, Joline Dalton, Alice Basinger, Can Ficicioglu, Ingo Helbig, Manuela Pendziwiat, Hiltrud Muhle, Katherine L. Helbig, Almuth Caliebe, René Santer, Kolja Becker, Sharon Suchy, Ganka Douglas, Francisca Millan, Amber Begtrup, Kristin G. Monaghan, and Heather C. Mefford. Tango2: expanding the clinical phenotype and spectrum of pathogenic variants. Genetics in Medicine, 21:601-607, Mar 2019. URL: https://doi.org/10.1038/s41436-018-0137-y, doi:10.1038/s41436-018-0137-y. This article has 67 citations and is from a highest quality peer-reviewed journal.

17. (mingirulli2020clinicalpresentationand pages 1-2): Nadja Mingirulli, Angela Pyle, Denisa Hathazi, Charlotte L. Alston, Nicolai Kohlschmidt, Gina O'Grady, Leigh Waddell, Frances Evesson, Sandra B. T. Cooper, Christian Turner, Jennifer Duff, Ana Topf, Delia Yubero, Cristina Jou, Andrés Nascimento, Carlos Ortez, Angels García‐Cazorla, Claudia Gross, Maria O'Callaghan, Saikat Santra, Maryanne A. Preece, Michael Champion, Sergei Korenev, Efsthatia Chronopoulou, Majumdar Anirban, Germaine Pierre, Daniel McArthur, Kyle Thompson, Placido Navas, Antonia Ribes, Frederic Tort, Agatha Schlüter, Aurora Pujol, Raquel Montero, Georgia Sarquella, Hanns Lochmüller, Cecilia Jiménez‐Mallebrera, Robert W. Taylor, Rafael Artuch, Janbernd Kirschner, Sarah C. Grünert, Andreas Roos, and Rita Horvath. Clinical presentation and proteomic signature of patients with tango2 mutations. Journal of Inherited Metabolic Disease, 43:297-308, Aug 2019. URL: https://doi.org/10.1002/jimd.12156, doi:10.1002/jimd.12156. This article has 55 citations and is from a peer-reviewed journal.

18. (sandkuhler2026crossspeciesevaluationof pages 15-16): Sarah E Sandkuhler, Kayla S Youngs, Laura Owlett, Monica B Bandora, Aaliya Naaz, Euri S Kim, Lili Wang, Andrew P Wojtovich, Vandana A Gupta, Michael Sacher, and Samuel J Mackenzie. Heme’s relevance genuine? re-visiting the roles of tango2 homologs including hrg-9 and hrg-10 in c. elegans. Apr 2026. URL: https://doi.org/10.7554/elife.105418, doi:10.7554/elife.105418.

19. (miyake2022cardiaccrisescardiac pages 8-9): Christina Y. Miyake, Erica J. Lay, Cheyenne M. Beach, Scott R. Ceresnak, Caridad M. Delauz, Taylor S. Howard, Christopher M. Janson, Kate Jardine, Prince J. Kannankeril, Maina Kava, Jeffrey J. Kim, Leonardo Liberman, Scott L. Macicek, Tam Dam Pham, Terry Robertson, Santiago O. Valdes, Gregory Webster, Sara B. Stephens, Diana M. Milewicz, Mahshid Azamian, Saad A. Ehsan, Kimberly M. Houck, Claudia Soler-Alfonso, Kevin E. Glinton, Mustafa Tosur, Na Li, Weiyi Xu, Seema R. Lalani, and Lilei Zhang. Cardiac crises: cardiac arrhythmias and cardiomyopathy during tango2 deficiency related metabolic crises. Heart Rhythm, 19:1673-1681, Oct 2022. URL: https://doi.org/10.1016/j.hrthm.2022.05.009, doi:10.1016/j.hrthm.2022.05.009. This article has 37 citations and is from a peer-reviewed journal.

20. (dołega2024clinicalspectrumdiagnosis pages 4-7): Marcin Dołęga, Piotr Gacka, Olrgierd Dróżdż, Joanna Gołda, Julia Mężyk, and Aleksandra Snopkowska. Clinical spectrum, diagnosis, and management of tango2 deficiency disorder: a comprehensive review. Quality in Sport, 21:54001, Aug 2024. URL: https://doi.org/10.12775/qs.2024.21.54001, doi:10.12775/qs.2024.21.54001. This article has 2 citations.

21. (dołega2024clinicalspectrumdiagnosis pages 1-4): Marcin Dołęga, Piotr Gacka, Olrgierd Dróżdż, Joanna Gołda, Julia Mężyk, and Aleksandra Snopkowska. Clinical spectrum, diagnosis, and management of tango2 deficiency disorder: a comprehensive review. Quality in Sport, 21:54001, Aug 2024. URL: https://doi.org/10.12775/qs.2024.21.54001, doi:10.12775/qs.2024.21.54001. This article has 2 citations.

22. (casey2022glycerolipiddefectsin pages 1-5): Jennifer G Casey, Euri S Kim, Brian S Tao, Arian Mansur, E. Diane Wallace, and Vandana A Gupta. Glycerolipid defects in skeletal muscle contribute to rhabdomyolysis in tango2 deficiency. bioRxiv, Nov 2022. URL: https://doi.org/10.1101/2022.11.12.516274, doi:10.1101/2022.11.12.516274. This article has 1 citations.

Artifacts

• Edison artifact artifact-00